Company newsForm 8-K and release
SELLAS says Phase 3 REGAL trial of galinpepimut-S met its primary endpoint in AML
In the trial, the cancer vaccine reduced the risk of death by 41% compared with best available treatment.
GetSignal
On November 17, 2026, SELLAS Life Sciences Group announced positive topline results from the pivotal randomized Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The trial met its primary endpoint of overall survival (OS).
The trial tested GPS as maintenance monotherapy in patients who reached a second or later complete remission, or complete remission with insufficient platelet recovery, after second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation. A total of 126 patients were randomized 1:1 to GPS or investigator's choice of best available treatment (BAT).
Median OS was 24.0 months for GPS-treated patients, compared with 14.7 months with BAT. The hazard ratio was 0.59, with a two-sided p-value of 0.035. The company said the improvement in OS was statistically significant and clinically meaningful.
The company said GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate (grade 1/2), most commonly local injection site reactions.
The primary endpoint analysis was conducted after a pre-specified 80 deaths. The company said it plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and to advance preparations for a Biologics License Application (BLA) submission for GPS in the first half of 2027. The company said a full evaluation of secondary endpoints is underway and will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal.
Key facts
- Trial
- REGAL, Phase 3
- Risk of death
- 41% reduction (hazard ratio of 0.59)
- Median overall survival
- 24.0 months with GPS vs. 14.7 months with best available treatment
- P-value
- Two-sided p=0.035
- Patients randomized
- 126
Sources: Form 8-K filed November 17, 2026, and the company's release on GlobeNewswire, November 17, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
SELLAS Life Sciences Group first, then the newest- SELLAS Life Sciences Group closes public offering for $172.5 million gross
SLS · SELLAS Life Sciences Group · Company release · Nov 20, 2026
- SELLAS Life Sciences Group prices 11,538,462-share offering at $13.00 per share
SLS · SELLAS Life Sciences Group · Form 8-K and release · Nov 17, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
